Please assess the completion status of the following clinical trial:

Trial Title: Tailored Treatment of Permanent Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA:~* History of symptomatic, continuous atrial fibrillation defined as: Continuous atrial fibrillation lasting greater than 1 year but less than 4 years or nonself-terminating atrial fibrillation, lasting greater than 7 days but no more than 1 year, with at least one failed direct current cardioversion. A failed cardioversion was defined as an unsuccessful cardioversion or one in which normal sinus rhythm was established but not maintained beyond 7 days.~* Atrial fibrillation symptoms included the following: palpitations, fatigue,exertional dyspnea, exercise intolerance~* Age between 18 and 70 years~* Failure of at least one Class I or III rhythm control drug~* Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study.~EXCLUSION CRITERIA:~* Structural heart disease of clinical significance including:~  * Previous cardiac surgery (excluding coronary artery bypass graft and mitral valve repair)~ * Symptoms of congestive heart failure including, but not limited to, New York Heart Association (NYHA) Class III or IV congestive heart failure and/or documented ejection fraction \<40% measured by acceptable cardiac testing~ * Left atrial diameter \>55 mm~ * Moderate to severe mitral or aortic valvular heart disease~ * Stable/unstable angina or ongoing myocardial ischemia~ * Myocardial infarction (MI) within 3 months of enrollment~ * Congenital heart disease (not including atrial septal defect or patent foramen ovale without a right to left shunt) where the underlying abnormality increases the risk of an ablative procedure~ * Prior atrial septal defect of patent foramen ovale closure with a device using a percutaneous approach~ * Hypertrophic cardiomyopathy (left ventricular septal wall thickness \>1.5 cm)~ * Pulmonary hypertension (mean or systolic pulmonary artery pressure \>50 mm Hg on Doppler echo)~* Any prior ablation for atrial fibrillation~* Enrollment in any other ongoing arrhythmia study~* Any ventricular tachyarrhythmia currently being treated where the arrhythmia or the management may interfere with this study~* Active infection or sepsis~* Any history of cerebral vascular disease including stroke or transient ischemic attacks~* Pregnancy or lactation~* Left atrial thrombus at the time of ablation~* Untreatable allergy to contrast media~* Any diagnosis of atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiovascular causes~* History of blood clotting (bleeding or thrombotic) abnormalities~* Known sensitivities to heparin or warfarin~* Severe chronic obstructive pulmonary disease (defined as forced expiratory volume 1 (FEV1) \<1)~* Severe co-morbidity or poor general physical/mental health that, in the opinion of the investigator, will not allow the subject to be a good study candidate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Ablation Management
- 2 (Type: ACTIVE_COMPARATOR): Medical Management

Based on this trial design, predict the completion outcome and termination type (if applicable).